Investors & Media

December 22, 2025

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

December 16, 2025

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace

December 8, 2025

Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa

December 2, 2025

Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium

November 13, 2025

Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025

November 3, 2025

Immutep Receives A$4.6 million R&D Tax Incentive from French Government

November 13, 2025

CTOS 2025 Annual Meeting – EFTISARC-NEO trial with neoadjuvant eftilagimod alfa (Soft Tissue Sarcoma)

October 29, 2025

Immutep Corporate Presentation

October 19, 2025

ESMO Congress 2025 – EFTISARC-NEO (Soft Tissue Sarcoma)

October 18, 2025

ESMO Congress 2025 – INSIGHT-003 (First Line Non-Small Cell Lung Cancer)

October 18, 2025

ESMO Congress 2025 – TACTI-004 (First Line Non-Small Cell Lung Cancer)

December 12, 2024

ESMO Immuno-Oncology 2024 – TACTI-003, Cohort B (Metastatic Head and Neck Squamous Cell Carcinoma)